FDA approves first generic moxidectin drench for sheep: full analysis

The FDA has approved the first generic moxidectin oral drench for sheep, adding a new over-the-counter option for treatment and control of internal parasites in a species with a limited approved drug toolbox. The newly approved product, Moxidectin Oral Drench for Sheep from First Priority Inc. of Elgin, Illinois, was announced by FDA’s Center for Veterinary Medicine on April 29, 2026. FDA said the product is bioequivalent to the reference listed drug, Elanco’s Cydectin Oral Drench for Sheep, which was originally approved on November 30, 2005. (fda.gov)

The approval comes against a backdrop of persistent concern about parasite control in small ruminants. FDA has separately noted that sheep and goats have relatively few approved antiparasitic drugs in the U.S., and that resistance has emerged to each active ingredient currently marketed for these species, including moxidectin. That context is important: while a generic approval can improve availability and competition, it doesn’t create a new mechanism of action or solve the resistance pressures that have built over years of use. (fda.gov)

According to the FDA approval materials, the generic is a 1 mg/mL oral solution supplied in 1 L and 4 L containers and labeled for administration at 1 mL per 11 lb, delivering 0.2 mg/kg. The indication includes both adult and larval (L4) stages of a broad list of gastrointestinal nematodes, including Haemonchus contortus, Teladorsagia circumcincta, T. trifurcata, Trichostrongylus axei, T. colubriformis, T. vitrinus, Cooperia curticei, C. oncophora, Oesophagostomum columbianum, O. venulosum, Nematodirus battus, N. filicollis, and N. spathiger. The product remains OTC, carries a 7-day meat withdrawal, and should not be used in female sheep producing milk for human consumption because a milk withholding time hasn’t been established. (animaldrugsatfda.fda.gov)

Regulatorily, this was an abbreviated new animal drug application, or ANADA, rather than a full new animal drug approval. FDA’s freedom of information summary says First Priority received a biowaiver because the generic is a solution with the same active ingredient, concentration, and dosage form as the reference product, and without inactive ingredients expected to meaningfully affect bioavailability. That means the approval pathway relied on demonstrating equivalence to the approved brand product rather than re-running the full effectiveness and target animal safety package. (animaldrugsatfda.fda.gov)

Industry and expert commentary around this specific approval appears limited so far, but the broader expert view on moxidectin is clear: access matters, stewardship matters more. FDA has warned that parasite resistance is already established across the currently marketed actives for sheep and goats. The American Consortium for Small Ruminant Parasite Control has also highlighted substantial moxidectin resistance in field testing and has cautioned clinicians to use the sheep oral drench product appropriately rather than substitute unapproved formulations. (fda.gov)

Why it matters: For veterinary professionals, the practical upside is straightforward. A generic moxidectin drench could improve supply resilience and create some pricing pressure in a narrow market, potentially making labeled therapy more accessible for sheep operations. That may be especially relevant in food-animal practice, where cost and availability can shape whether producers use approved products or look elsewhere. But the clinical message is more nuanced: because this is the same active ingredient as Cydectin, veterinarians shouldn’t view the approval as a new resistance-management tool. It’s another labeled source of an existing macrocyclic lactone, not a new class. (animaldrugsatfda.fda.gov)

That distinction matters in flock health planning. Moxidectin has long been a valuable option in sheep parasite control, yet its usefulness depends heavily on how it’s deployed. The FDA’s own background materials emphasize that near-total parasite elimination is not sustainable and can accelerate resistance selection. For veterinarians advising pet parents and producers who keep sheep, that reinforces the value of diagnostics, targeted selective treatment, accurate dosing, and clear communication about withdrawal times and milk-use restrictions. (fda.gov)

What to watch: The next signals will likely be commercial rather than scientific: how quickly the product reaches distribution, whether competitors follow with additional generic filings in small-ruminant parasiticides, and whether the approval improves use of labeled products without worsening resistance pressure. In the near term, the bigger veterinary watchpoint remains parasite stewardship, not just product availability. (fda.gov)